# An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

> **NCT00643851** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 994 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Metformin XR

## Key facts

- **NCT ID:** NCT00643851
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 994 (ACTUAL)
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00643851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00643851, "An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00643851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*